Early detection of kidney damage: How AGEs may support CKD management
Chronic kidney disease often develops silently. eGFR declines gradually, microalbuminuria appears late, and by the time clinical signs emerge, structural damage is typically already present. Yet there is something measurable, if you know where to look.
AGEs (Advanced Glycation End-products) are harmful compounds that accumulate due to metabolic stress, oxidative damage, and chronic hyperglycemia. They play a key role in inflammatory and fibrotic pathways in the kidneys, including through activation of the RAGE receptor. This accumulation may contribute to glomerular damage and progression of kidney function decline.
Research suggests that elevated AGE levels correlate with reduced eGFR and that AGE accumulation may be detectable even before albuminuria or creatinine changes occur. This makes AGEs a potential complementary marker for identifying patients at risk of CKD progression.
Non-invasive skin measurement of AGEs is increasingly studied as an additional parameter in early metabolic risk detection. Among CKD patients, multiple clinical studies have shown that elevated AGE levels – measured through skin autofluorescence – are associated with faster renal decline, cardiovascular complications, and mortality. Although AGE measurement is not yet included in clinical guidelines, it increasingly offers clinicians valuable insights for risk stratification and monitoring of vulnerable patients.
Even individuals with normal albuminuria and eGFR may show elevated AGE levels. In primary diabetes care settings, clinicians are increasingly asking whether AGE measurement could help identify metabolically stressed patients who appear low-risk based on standard parameters. Clinical research supports this: within this seemingly stable group, elevated AGE levels are associated with higher cardiovascular risk and faster renal decline. AGE measurement may therefore help detect patients who would otherwise remain unnoticed.
AGE measurement is quick, painless, and non-invasive. It does not replace existing markers, but it may offer an important additional dimension to the current CKD risk profile.
We share this to raise awareness of the role of metabolic stress as a silent predictor of kidney damage. If you work in preventive nephrology, diabetes care, or multidisciplinary risk teams, it may be valuable to consider AGEs as part of your assessment.
Would you like more information? Contact us or join our quarterly newsletter for clinical updates on AGEs in kidney care.
Sources
Yamagishi S, et al. Role of AGEs in diabetic nephropathy. Curr Drug Targets. 2007.
Goh SY, Cooper ME. Clinical importance of AGEs in CKD. Nephrol Dial Transplant. 2008.
Meerwaldt R, et al. Skin autofluorescence and renal function decline. Nephrol Dial Transplant. 2005.